Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tivozanib + capecitabine
- Development stage
- Phase 1
- Lead developer
- AVEO Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tivozanib + capecitabine is a combination of two oral small molecule drugs used in oncology, primarily for the treatment of advanced cancers. Tivozanib is a selective tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3, thereby inhibiting angiogenesis and tumor growth[6][8]. Capecitabine is an oral prodrug that is converted to 5-fluorouracil (5-FU) in the body; it interferes with DNA synthesis by inhibiting thymidylate synthase, leading to inhibition of cancer cell proliferation[4][2]. This combination may be explored in clinical trials for synergistic effects against certain solid tumors.
02
Targets
TS (Thymidylate synthase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on tivozanib + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tivozanib + capecitabine.